MAP2K7 and melanoma: In this study, we reviewed all cases of patients treated with SRS for melanoma metastases in an effort to quantify the degree to which BRAF/MEK targeted therapy and immunotherapy show an extracranial response with the development of intracranial metastatic diseases.